BNP and echocardiographic parameters in patients with chronic kidney disease and dialyzed patients

Czech version

Authors: I. Valočiková ¹; G. Valočik ²; B. Krištofová ¹; Ľ. Družbacká ²; R. Roland ³; P. Mitro ²
Authors‘ workplace: I. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednostka prof. MU Dr. Ivica Lazúrová, CSc. ¹; III. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednosta doc. MU Dr. Peter Mitro, Ph. D. ²; FRESENIUS, Nefrologické a dialyzačné centrum Košice, Slovenská republika, prednosta prim. MU Dr. Robert Roland ³
Published in: Vnitř Lék 2009; 55(10): 934-939
Category: Original Contributions

Overview

We assessed the relation between BNP levels and some echocardiographic parameters of systolic and diastolic function of the left ventricle in 49 patients (mean age 69.39 ± 8.47 years) with chronic kidney disease in different stages of chronic renal failure according to K/ DOQI and in 45 subjects (mean age 52.6 ± 14.85 years) on dialysis. Median for BNP in the group of patients with chronic renal failure was 132 pg/ ml, and in dialysis subjects 320 pg/ ml. None of our patients had clinical signs of heart failure during the last six months. Using a method of correlation matrix we found the left ventricular mass and its indexed value as a common indicator of increased BNP level in both groups of patients (dialysis patients, p = 0.0003, and p = 0.0005, respectively; patients with chronic renal failure, p = 0.03, and p = 0.04, respectively). Further analysis proved that in the group of dialysis patients the main determinants of increased BNP level were volumes of the left heart side: left ventricular enddiastolic volume (p = 0.004), endsystolic volume (p = 0.01), and left atrial volumes (maximal, minimal, and total atrial stroke volume; p = 0.004, p = 0.009 a p = 0.04, respectively). In the group of patients with chronic renal failure the major contributors to increased BNP level were echocardiographic parameters of diastolic filling assessed from transmitral and pulmonary venous flow: E wave (p = 0.001), A wave (p = 0.01), E/ A (p

Key words:
chronic renal disease –⁠ chronic renal failure –⁠ systolic and diastolic dysfunction –⁠ cardiac biomarkers –⁠ BNP

Sources

1. Joffy L, Rosner MH. Natriuretic peptides in ESRD. Am J Kidney Dis 2005; 46 : 1 –⁠ 10.

2. Roberts MA, Hare DL, Ratnaike S et al. Cardiovascular Biomarkers in CKD: Pathophysiology and Implication for Clinical Management of Cardiac Disease. Am J Kidney Dis 2006; 48 : 341 –⁠ 360.

3. Totsune K, Takahashi K, Satoh F et al. Urinary immunoreactive brain natriuretic peptide in patients with renal disease. Regul Pept 1996; 63 : 141 –⁠ 147.

4. Vasavada N, Agarwal R. Role of excess volume in the pathopsysiology of hypertension in chronic kidney disease. Kidney Int 2003; 64 : 1772 –⁠ 1779.

5. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351 : 1296 –⁠ 1305.

6. Shlipak MG, Heidenreich PA, Noguchi H et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137 : 555 –⁠ 562.

7. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351 : 1285 –⁠ 1295.

8. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2000; 13 : 1918 –⁠ 1927.

9. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55 : 613 –⁠ 618.

10. Herzog CA. Dismal long‑term survival of dialysis patients after acute myocardial infarction: can we alter the outcome? Nephrol Dial Transplant 2002; 17 : 7 –⁠ 10.

11. Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in haemodialysis patients: an evidence‑based review. Hemodial Int 2007; 11 : 1 –⁠ 14.

12. Logar CM, Herzog CA, Beddhu S. Diagnosis and therapy of coronary artery disease in renal failure, end‑stage renal disease, and renal transplant population. Am J Med Sci 2003; 325 : 214 –⁠ 227.

13. Garg AX, Clark WF, Haynes RB et al. Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 2002; 61 : 1486 –⁠ 1494.

14. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow‑up and outcomes among a population with chronic kidney disease in a large managed care organisation. Arch Intern Med 2004; 164 : 659 –⁠ 663.

15. Sarnak MJ, Coronado BE, Greene T et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57 : 327 –⁠ 335.

16. Ronco C, Haapio M, House AA et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52 : 1527 –⁠ 1539.

17. Cameron SJ, Green GB. Cardiac biomarkers in renal disease: the fog is slowly lifting. Clinical Chem 2004; 50 : 2233 –⁠ 2235.

18. Zoccali C. Biomarkers in chronic kidney disease: utility and issues towards better understanding. Curr Opin Nephrol Hypertens 2005; 14 : 532 –⁠ 537.

19. Mallamaci F, Tripepi G, Cutrupi S et al. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005; 67 : 2330 –⁠ 2337.

20. Cazzovillan S, Ratanarat R, Segala C et al. Inflammation and subclinical infection in chronic kidney disease: a molecular approach. Blood Purif 2007; 25 : 69 –⁠ 76.

21. Agarwal S, Dangri P, Kalra OP et al. Echocardiographic assessment of cardiac dysfunction in patients of chronic renal failure. JIAM 2003; 4 : 296 –⁠ 303.

22. de Almeida EA, de Oliveira EI, Lopés JA et al. Diastolic function in several stages of chronic kidney disease in patients with autosomal dominant polycystic kidney disease: a tissue doppler imaging study. Kidney Blood Press Res 2007; 30 : 234 –⁠ 239.

23. Miyazato J, Horio T, Takiuchi S et al. Left ventricular diastolic dysfuction in patients with chronic renal failure: impact of diabetes mellitus. Diabet Med 2005; 22 : 730 –⁠ 736.

24. Hayashi SY, Rohani M, Lindholm B. Left ventricular function in patients with chronic kidney disaese evaluated by colour tissue Doppler velocity imaging. Nephrol Dial Transplant 2006; 21 : 125 –⁠ 132.

25. Wanic -⁠ Kossowska M, Lehmann P, Czekalski S. Left ventricular systolic and diastolic dysfunction in patients with chronic renal failure treated with hemodialysis. Pol Arch Med Wewn 2003; 109 : 365 –⁠ 373.

26. Ludka O, Špinar J, Vítovcová L et al. Význam stanovení NT -⁠ proBNP a big endotelinu pro diagnostiku chronického srdečního selhání u nemocných v pravidelném hemodialyzačním programu. Vniř Lék 2007; 53 : 38 –⁠ 45.

27. Ludka O, Špinar J, Vítovcová L et al. Variabilita plazmatických hladin big endotelinu a NT -⁠ proBNP u nemocných se srdečním selháním v chronickém hemodialyzačním programu. Vniř Lék 2007; 53 : 1177 –⁠ 1181.

28. Berger AK, Duval S, Krumholz HM. Aspirin, beta‑blocker and angiotensin‑converting enzyme inhibitor therapy in patients with end‑stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42 : 201 –⁠ 208.

29. French WJ, Wright RS. Renal insufficiency and worsened prognosis with STEMI: a call for action. J Am Coll Cardiol 2003; 42 : 1544 –⁠ 1546.